LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.65
-0.21 (-3.58%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.86
Open5.88
Bid5.64 x 800
Ask6.35 x 2900
Day's Range5.56 - 5.89
52 Week Range4.25 - 13.97
Volume176,116
Avg. Volume676,732
Market Cap600.437M
Beta (3Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX)
    Simply Wall St.3 days ago

    Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX)

    Lonnel Coats has been the CEO of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) since 2014. This analysis aims first to...

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

    Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for LXRX with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding LXRX is favorable, with net inflows of $2.55 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of LXRX earnings conference call or presentation 1-May-19 12:00pm GMT

    Q1 2019 Lexicon Pharmaceuticals Inc Earnings Call

  • Here’s What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX)
    Insider Monkeylast month

    Here’s What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX)

    The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]

  • Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

    Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -31.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Lexicon Pharmaceuticals Inc (LXRX) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Lexicon Pharmaceuticals Inc (LXRX) Q1 2019 Earnings Call Transcript

    LXRX earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    Lexicon: 1Q Earnings Snapshot

    On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 21 cents. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Will Lexicon Pharmaceuticals (LXRX) Report Negative Q1 Earnings? What You Should Know
    Zacks2 months ago

    Will Lexicon Pharmaceuticals (LXRX) Report Negative Q1 Earnings? What You Should Know

    Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Did You Manage To Avoid Lexicon Pharmaceuticals's (NASDAQ:LXRX) Painful 55% Share Price Drop?
    Simply Wall St.2 months ago

    Did You Manage To Avoid Lexicon Pharmaceuticals's (NASDAQ:LXRX) Painful 55% Share Price Drop?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But l...

  • AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes
    Zacks3 months ago

    AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes

    AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.

  • Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
    Zacks3 months ago

    Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

    Key highlights of the past week are multiple study failures and other pipeline updates.

  • Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug
    Zacks3 months ago

    Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

    FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.

  • AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes
    Zacks3 months ago

    AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes

    AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.

  • What's Next for Lexicon Pharmaceuticals?
    Motley Fool3 months ago

    What's Next for Lexicon Pharmaceuticals?

    American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.

  • This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment
    Investor's Business Daily3 months ago

    This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment

    Shares of French pharmaceutical giant Sanofi dipped Friday after the FDA rejected its application for a diabetes treatment created under a partnership with Lexicon Pharmaceuticals.

  • Why Zuora, Greenbrier, and Lexicon Pharmaceuticals Slumped Today
    Motley Fool3 months ago

    Why Zuora, Greenbrier, and Lexicon Pharmaceuticals Slumped Today

    Poor prospects and a big disappointment hit these stocks.

  • Reuters3 months ago

    FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

    The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc intended for use with insulin in patients with type 1 diabetes, the companies said on Friday. The decision comes about two months after an FDA advisory panel failed to reach a consensus over whether the once-daily oral drug, sotagliflozin, should be approved as an add-on to insulin therapy. The setback comes as Sanofi works to revive declining sales from its diabetes division, and as the French drugmaker faces increasing pressure from politicians and patient advocacy groups over the rising cost of its insulin products.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of LXRX earnings conference call or presentation 13-Mar-19 12:00pm GMT

    Q4 2018 Lexicon Pharmaceuticals Inc Earnings Call

  • Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
    Zacks3 months ago

    Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

    Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

  • GuruFocus.com3 months ago

    Lexicon Pharmaceuticals Inc (LXRX) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. Warning! GuruFocus has detected 3 Warning Signs with LXRX. For the last quarter Lexicon Pharmaceuticals Inc reported a revenue of $17.1 million, compared with the revenue of $33.05 million during the same period a year ago.

  • Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call Transcript

    LXRX earnings call for the period ending December 31, 2018.

  • Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
    Zacks3 months ago

    Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

    Lexicon (LXRX) delivered earnings and revenue surprises of 42.86% and 24.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Lexicon: 4Q Earnings Snapshot

    On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 16 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...